Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 13/20 | 0.47 |
| ▸ | BRD2 | P25440 | 2/20 | 0.42 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.42 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16651407 | 0.88 | BRD4 (0.47) | PTGS2PTGS1BRD4EPAS1HSPB1 | |
| SCHEMBL21191046 | 0.87 | BRD4 (0.45) | PTGS2PTGS1BRD4EPAS1HSPB1 | |
| SCHEMBL21190879 | 0.85 | BRD4 (0.47) | PTGS2PTGS1BRD4EPAS1HSPB1 | |
| SCHEMBL21191120 | 0.84 | PTGS2 (0.47) | PTGS2PTGS1BRD4HSPB1MAPK14 | |
| SCHEMBL15069481 | 0.84 | BRD4 (0.48) | PTGS2BRD4HSPB1MAPK14 | |
| SCHEMBL16650216 | 0.83 | BRD4 (0.50) | PTGS2BRD4BRD2BRD3BRDT | |
| SCHEMBL20268765 | 0.81 | HSPB1 (0.63) | PTGS2HSPB1 | |
| SCHEMBL16651736 | 0.81 | BRD4 (0.46) | PTGS2BRD4BRD2BRD3BRDT | |
| SCHEMBL29533045 | 0.80 | HSPB1 (0.39) | PTGS2BRD4HSPB1MAPK14 | |
| SCHEMBL15069672 | 0.80 | HSPB1 (0.39) | PTGS2BRD4HSPB1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3741758-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2020-11-25 | — | — | EP | disclosed |
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-12 | — | — | US | disclosed |
| WO-2019141131-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | 中国科学院上海药物研究所 | 2019-07-25 | — | — | WO | disclosed |
| WO-2018086604-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATIONS THEREOF | 山东罗欣药业集团股份有限公司 | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | BRD4, BRD1, BRD3 | PTGS2 3990/4885PTGS1 2876/4885BRD4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.